First-Trimester Impetigo Herpetiformis Leads to Stillbirth: A Case Report-Reference-Cited by-同舟云学术

First-Trimester Impetigo Herpetiformis Leads to Stillbirth: A Case Report

Published:2022-05 Issue:5 Volume:12 Page:1271-1279
ISSN:2193-8210
Container-title:Dermatology and Therapy
language:en
Short-container-title:Dermatol Ther (Heidelb)

Author:

Liu Jue,Ali Kamran,Lou Haiyue,Wang Lingling,Wu Liming^ORCID

Publisher

Springer Science and Business Media LLC

Subject

Dermatology

Link

https://link.springer.com/content/pdf/10.1007/s13555-022-00735-9.pdf

Reference37 articles.

1. Von HF. Ueber einzelne während Schwangerschaft, des Wochenbettes und bei Uterinalkrankheiten der Frauen zu beobachtende Hautkrankheiten. Wien Med Wochenschr. 1872;22:1197–202.

2. Samdani AJ. Pregnancy dermatoses: three year study. Pak J Med Sci. 2004;20:292–5.

3. Lotem M, et al. Impetigo herpetiformis: a variant of pustular psoriasis or a separate entity? J Am Acad Dermatol. 1989;20(2 Pt 2):338–41.

4. Trivedi MK, Vaughn AR, Murase JE. Pustular psoriasis of pregnancy: current perspectives. Int J Womens Health. 2018;10:109–15.

5. Kroumpouzos G, Cohen LM. Dermatoses of pregnancy. J Am Acad Dermatol. 2001;45(1):1–19 (quiz 19-2).

Cited by 7 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Successful Treatment of Generalized Pustular Psoriasis during Pregnancy by Cyclosporin and Etanercept: Own Experience and Review of Literature;Annals of Dermatological Research;2024-02-27

2. Autoinflammatory Keratinization Diseases—The Concept, Pathophysiology, and Clinical Implications;Clinical Reviews in Allergy & Immunology;2023-12-16

3. Impetigo herpetiformis in the second trimester: a case report and review of the literature;Journal of International Medical Research;2023-12

4. Generalised Pustular Psoriasis of Pregnancy-Induced In Vitro Fertilisation Therapy: A Case Report and a Recommendation for Early Diagnosis;Indian Journal of Dermatology;2023-07

5. Terbinafine Induced Acute Generalized Exanthematous Pustulosis Treated with Adalimumab: Recalcitrant to Systemic Corticosteroid Therapy;Clinical, Cosmetic and Investigational Dermatology;2023-01